Renub Research has recently published a report titled “ United States Biopsy Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis,” providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension in the United States Biopsy Market. The United States Biopsy Industry shall expand at a CAGR of nearly 4.46% from 2023 to 2028. A biopsy is a medical procedure involving taking a tissue or cell sample from the body to diagnose or rule out cancer, infections, or other conditions. It can be performed using a needle or surgical techniques, depending on the location of the tissue and the reason for the biopsy.
The growing prevalence of cancer has resulted in an augmented need for diagnostics procedures, including biopsies, thereby contributing to the expansion of the United States’ biopsy market. The American Cancer Society projects that approximately 1.9 million new cancer cases (equivalent to around 5,370 cases per day) and 609,820 cancer-related fatalities (about 1,670 deaths each day) will occur in the United States 2023.
The demand for less invasive procedures is increasing as patients are becoming more inclined towards procedures that offer benefits such as faster recovery and reduced risks compared to traditional surgical methods, thereby fuelling the growth of the United States biopsy market. Moreover, the increasing recognition of the significance of early cancer detection is also playing a crucial role in the surging demand for biopsies.
Biopsy technology has undergone noteworthy advancements, resulting in increased precision and reduced invasiveness of the procedure. The utilization of image-guided biopsies, including ultrasound or CT-guided biopsies, is an exemplar of these advancements, which has contributed to enhancing the accuracy and safety of the procedure.
The high incidence and mortality rate of lung cancer, along with the increased use of low-dose CT screening, have contributed to the prominence of lung cancer in the United States Biopsy Market
Lung cancer is one of the highly prevalent cancers in the United States, with a high incidence rate and mortality rate. According to the American Cancer Society’s projections for 2023, there will be approximately 238,340 new lung cancer cases in the United States, with 117,550 cases in men and 120,790 cases in women. Furthermore, an estimated 127,070 deaths from lung cancer shall occur in the same year, with 67,160 deaths in men and 59,910 deaths in women.
Obtaining a tissue sample through biopsy is necessary for accurate diagnosis and treatment planning of lung cancer due to the difficulty in diagnosing the disease without it. Moreover, the rising utilization of low-dose CT screening in high-risk populations has resulted in the discovery of more suspicious nodules, often necessitating a biopsy for diagnosis. Additionally, the demand for precise diagnosis through biopsy has increased due to the development of targeted therapies for specific lung cancer mutations, requiring molecular tissue testing to determine treatment decisions.
Rising incidence of breast cancer and a shift towards more conservative diagnostics approaches have driven the growth in the United States biopsy market for breast cancer
Due to the growing incidence of breast cancer in women in the United States, there has been a surge in the volume of women referred for diagnostic tests, including biopsies. The American Cancer Society projects that in 2023, nearly 297,790 new cases of invasive breast cancer and diagnosis of 55,720 new cases of ductal carcinoma in situ (DCIS) will be in women in the country, with about 43,700 women expected to die from breast cancer. With more women being aware of and screening for breast cancer, more cases are being detected at earlier stages, leading to an increase in the number of women undergoing biopsies as part of the diagnostics process.
Improved breast imaging technology has led to the increased detection of suspicious breast lesions, which often require biopsy for confirmation or exclusion of cancer. Moreover, there has been a trend toward less invasive diagnostic methods prioritizing biopsy over surgical tissue removal, especially for small and non-palpable lesions, resulting in faster and more cost-effective results.
𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑫𝒆𝒕𝒂𝒊𝒍𝒔, 𝑮𝒓𝒂𝒃 𝒕𝒉𝒆 Free Sample Report: https://www.renub.com/request-sample-page.php?gturl=united-states-biopsy-testing-market-and-volume-analysis-to-2020-511-p.php
Competitive Landscape:
Some key companies operating in the region are Becton Dickenson & Company, Braun Melsungen AG (Germany), Cardinal Health Inc., Medtronic Plc., Hologic Inc., Bio-Rad Laboratories Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Roche Diagnostics, and Myriad Genetics Inc.
The competition in the United States biopsy market stems from the availability of different biopsies, each with distinct advantages and disadvantages offered by providers, creating a competitive environment. Additionally, the demand for biopsy equipment and supplies is competitive due to the numerous manufacturers. Moreover, there is fierce competition among healthcare providers, such as hospitals, clinics, and specialty centers, who offer biopsy services. Lastly, the growing demand for biopsies has increased the number of providers in the market, further intensifying the competition.
Market Summary:
- Market Segment- By market segment, the United States Biopsy Market, breakup in 8 viewpoints (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Colorectal Cancer, and Melanoma Cancer).
- Key Players- All the major players have been covered from 3 Viewpoints (Overview, Recent Developments, and Sales Analysis) Becton Dickenson & Company, Braun Melsungen AG (Germany), Cardinal Health Inc., Medtronic Plc., Hologic Inc., Bio-Rad Laboratories Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Roche Diagnostics, and Myriad Genetics Inc.
Related Reports
Cervical Cancer Screening Market, Size, Global Forecast 2023-2028
China Biopsy Market, Volume, Size, Forecast 2023-2027
United States Liquid Biopsy Market, Size, Global Forecast 2022-2027
Liquid Biopsy Market, Size, Global Forecast 2022-2027
China Molecular Diagnostics Market & Volume Forecast
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: [email protected]
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com